Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Position Raised by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC raised its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 20.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 386,211 shares of the company's stock after purchasing an additional 65,156 shares during the period. Lord Abbett & CO. LLC owned 0.79% of Enliven Therapeutics worth $8,690,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Invesco Ltd. lifted its stake in Enliven Therapeutics by 3.5% during the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company's stock worth $339,000 after purchasing an additional 508 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after buying an additional 1,114 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Enliven Therapeutics by 14.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after buying an additional 1,275 shares during the last quarter. MetLife Investment Management LLC raised its stake in Enliven Therapeutics by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock worth $489,000 after acquiring an additional 1,285 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Enliven Therapeutics by 17.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock worth $307,000 after acquiring an additional 1,980 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Insider Activity at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $18.69, for a total transaction of $60,742.50. Following the transaction, the chief financial officer now directly owns 23,000 shares of the company's stock, valued at $429,870. The trade was a 12.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $16.07, for a total transaction of $80,350.00. Following the completion of the sale, the insider now directly owns 997,688 shares of the company's stock, valued at $16,032,846.16. The trade was a 0.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,751 shares of company stock worth $1,331,288 in the last 90 days. Corporate insiders own 29.20% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday, March 21st.

Enliven Therapeutics Stock Up 3.3 %

NASDAQ ELVN traded up $0.66 on Friday, hitting $20.51. The stock had a trading volume of 221,177 shares, compared to its average volume of 259,995. The company's 50-day moving average is $19.17 and its two-hundred day moving average is $22.38. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -10.79 and a beta of 1.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.